Literature DB >> 16141545

Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs.

Toshiro Niwa1, Toshifumi Shiraga, Ikuko Ishii, Akira Kagayama, Akira Takagi.   

Abstract

The metabolic activities of six psychotropic drugs, diazepam, clotiazepam, tofisopam, etizolam, tandospirone, and imipramine, were determined for 14 isoforms of recombinant human hepatic cytochrome P450s (CYPs) and human liver microsomes by measuring the disappearance rate of parent compounds. In vitro kinetic studies revealed that Vmax/Km values in human liver microsomes were the highest for tofisopam, followed by tandospirone>clotiazepam>imipramine, diazepam, and etizolam. Among the recombinant CYPs, CYP3A4 exhibited the highest metabolic activities of all compounds except for clotiazepam and imipramine. The metabolism of clotiazepam was catalyzed by CYP2B6, CYP3A4, CYP2C18, and CYP2C19, and imipramine was metabolized by CYP2D6 most efficiently. In addition, the metabolic activities of diazepam, clotiazepam, and etizolam in human liver microsomes were inhibited by 2.5 microM ketoconazole, a CYP3A4 inhibitor, by 97.5%, 65.1%, and 83.5%, respectively, and the imipramine metabolism was not detected after the addition of 1 or 10 microM quinidine, a CYP2D6 inhibitor. These results suggest that the psychotropic drugs investigated are metabolized predominantly by CYP3A4, except that CYP2D6 catalyzes the metabolism of imipramine. In addition, this approach based on the disappearance rate appears to be useful for the identification of the responsible CYP isoform(s) of older drugs, for which metabolic profiles have not been reported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141545     DOI: 10.1248/bpb.28.1711

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  11 in total

1.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

2.  Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam.

Authors:  Mária Tóth; Sándor Drabant; Bálint Varga; Gyula Végso; Anna Cseh; Imre Szentpéteri; Imre Klebovich
Journal:  Eur J Clin Pharmacol       Date:  2007-11-08       Impact factor: 2.953

Review 3.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

4.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

Review 5.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

6.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jul-Sep       Impact factor: 2.441

7.  Development of a new predictive model for interactions with human cytochrome P450 2A6 using pharmacophore ensemble/support vector machine (PhE/SVM) approach.

Authors:  Max K Leong; Yen-Ming Chen; Hong-Bin Chen; Po-Hong Chen
Journal:  Pharm Res       Date:  2008-12-23       Impact factor: 4.200

8.  Effects of alcohol-induced increase in CYP2E1 content in human liver microsomes on the activity and cooperativity of CYP3A4.

Authors:  Bikash Dangi; Nadezhda Y Davydova; Marc A Maldonado; Armina Abbasi; Nikita E Vavilov; Victor G Zgoda; Dmitri R Davydov
Journal:  Arch Biochem Biophys       Date:  2020-11-13       Impact factor: 4.013

9.  Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.

Authors:  Rakshit S Tanna; Dan-Dan Tian; Nadja B Cech; Nicholas H Oberlies; Allan E Rettie; Kenneth E Thummel; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2020-10-22       Impact factor: 4.030

Review 10.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.